Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer's disease

D Kaur, V Sharma, R Deshmukh - Inflammopharmacology, 2019 - Springer
Alzheimer's disease (AD) is a neurodegenerative disease that is of high importance to the
neuroscience world, yet the complex pathogenicity is not fully understood. Inflammation is …

Immune attack: the role of inflammation in Alzheimer disease

FL Heppner, RM Ransohoff, B Becher - Nature Reviews Neuroscience, 2015 - nature.com
The past two decades of research into the pathogenesis of Alzheimer disease (AD) have
been driven largely by the amyloid hypothesis; the neuroinflammation that is associated with …

Current research therapeutic strategies for Alzheimer's disease treatment

J Folch, D Petrov, M Ettcheto, S Abad… - Neural …, 2016 - Wiley Online Library
Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the
developed countries. There is no effective treatment capable of slowing down disease …

Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside

F Islam, MH Nafady, MR Islam, S Saha, S Rashid… - Molecular …, 2022 - Springer
Alzheimer's disease (AD) is the most common cause of dementia and cognitive impairment;
yet, there is currently no treatment. A buildup of Aβ, tau protein phosphorylation, oxidative …

Towards modern-age advanced sensors for the management of neurodegenerative disorders: current status, challenges and prospects

A Gautam - ECS Sensors Plus, 2022 - iopscience.iop.org
Neurodegenerative diseases (NDD) are progressive degenerative disorders of the
neurological system with significant social impact worldwide. Their detection at the initial …

Polyphenols as potential metal chelation compounds against Alzheimer's disease

J Lakey-Beitia, AM Burillo, G La Penna… - Journal of …, 2021 - content.iospress.com
Alzheimer's disease (AD) is the most common neurodegenerative disease affecting more
than 50 million people worldwide. The pathology of this multifactorial disease is primarily …

[HTML][HTML] Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease

JL Cummings, K Zhong, JW Kinney, C Heaney… - Alzheimer's research & …, 2016 - Springer
Background We assessed the impact of retinoid X receptor (RXR) agonist bexarotene on
brain amyloid measured by amyloid imaging in patients with Alzheimer's disease (AD) in a …

[HTML][HTML] Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein

J Folch, M Ettcheto, D Petrov, S Abad, I Pedrós… - Neurología (English …, 2018 - Elsevier
Introduction Alzheimer disease (AD) is a major neurodegenerative disorder which
eventually results in total intellectual disability. The high global prevalence and the …

Alzheimer's disease mechanisms and emerging roads to novel therapeutics

C Sala Frigerio, B De Strooper - Annual review of neuroscience, 2016 - annualreviews.org
Ten years of remarkable progress in understanding the fundamental biochemistry of
Alzheimer's disease have been followed by ten years of remarkable and increasing clinical …

[HTML][HTML] Carotenoids as novel therapeutic molecules against neurodegenerative disorders: Chemistry and molecular docking analysis

J Lakey-Beitia, J Kumar D, ML Hegde… - International Journal of …, 2019 - mdpi.com
Alzheimer's disease (AD) is the most devastating neurodegenerative disorder that affects the
aging population worldwide. Endogenous and exogenous factors are involved in triggering …